Given the established association between lipid metabolism and disease risk for various types of cancer, for example, prostate cancer and bladder cancer [10, 11], this is not difficult to understand that the expression level of APOF has been found to be helpful in colorectal cancer (CRC) and cholangiocarcinoma (CHOL) screening [12, 13], predicting prognosis in hepatocellular carcinoma (LIHC) [14], and HPV status in oropharyngeal squamous cell carcinoma in previous studies [15]. This evidence concerns the gene APOF and cholangiocarcinoma.